12,743 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Purchased by HighVista Strategies LLC

HighVista Strategies LLC acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,743 shares of the company's stock, valued at approximately $603,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its position in shares of Kymera Therapeutics by 5.5% in the first quarter. California State Teachers Retirement System now owns 40,423 shares of the company's stock valued at $1,625,000 after purchasing an additional 2,102 shares during the period. Comerica Bank boosted its position in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company's stock worth $134,000 after acquiring an additional 400 shares during the last quarter. Virtu Financial LLC purchased a new stake in Kymera Therapeutics in the first quarter valued at approximately $207,000. DekaBank Deutsche Girozentrale increased its position in Kymera Therapeutics by 7.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 23,562 shares of the company's stock worth $950,000 after purchasing an additional 1,562 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Kymera Therapeutics by 175.4% during the second quarter. SG Americas Securities LLC now owns 10,887 shares of the company's stock worth $325,000 after purchasing an additional 6,934 shares during the period.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Pamela Esposito sold 13,500 shares of the business's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Price Performance

NASDAQ KYMR traded down $0.83 during mid-day trading on Tuesday, reaching $46.91. 446,438 shares of the company's stock traded hands, compared to its average volume of 584,858. Kymera Therapeutics, Inc. has a 1-year low of $20.32 and a 1-year high of $53.27. The company has a fifty day simple moving average of $46.82 and a 200-day simple moving average of $42.26.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business's revenue was down 20.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.90) EPS. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on KYMR shares. Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective for the company in a report on Monday, August 26th. Oppenheimer upped their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday, September 27th. Leerink Partnrs raised Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Truist Financial reissued a "buy" rating and set a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Finally, Guggenheim lifted their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $53.40.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.